FAQ
Please select a category below. A special page has been prepared to explain IMI's Intellectual Property (IP) Policy.
If you don't find a answer to your question please don't hesitate to contact us with our contact form.
Biotechnology companies are one of the key sources of new technologies and their participation in IMI will be important to its success. They have been involved in establishing the IMI research priorities, through consultative workshops and through work with representative associations such as European Biopharmaceutical Enterprises (EBE) and EuropaBio. Small biotech companies will also have representation in the governance structure of IMI through the Stakeholder forum.
The collaborative approach fostered by IMI will reduce risks for small companies and help them -like pharmaceutical companies- to develop medicines more efficiently, through access to new tools and ways of working. The project also offers opportunities for companies specialized in the development of tools and technologies supporting medicine development, such as in vitro, in vivo and in silico modelling It is anticipated that research under IMI will lead to more discovery and development of better medicines, for a wide variety of conditions. This can only be positive for patients. Patient representatives will play an active role in the IMI governance structure through the Stakeholder forum and are likely to be involved in many projects. They will contribute to discussions on new concepts for clinical trials and risk assessment with regulatory authorities, as these areas affect them and their access to innovative medicines directly. Academics are a key engine for novel scientific breakthroughs and their role in IMI will be essential. They will be represented in the IMI governance structure through the Stakeholder forum. IMI will constitute a framework within which academics will be able to bid for work and establish European collaborations. Additionally IMI will help them to define competitive and relevant R&D programmes, as well as offer them improved infrastructure with state-of-the-art technological equipment. The Education & Training pillar of the IMI will foster the development of new courses, networks and an academy. Current instruments have a high administrative burden and do not have the flexibility for industry and partners to work together easily. The IMI will enable industry to work more effectively with other stakeholders than previous framework programmes have allowed, providing a specific framework and co-ordination geared towards medical research. |
|